Human atrial natriuretic peptide (hANP) has no effect upon dopaminergic pathways: preliminary evidence in nude mice bearing heterotransplanted human CONN's adenoma tissue.
To examine whether human atrial natriuretic peptide (hANP) has an agonistic effect on dopaminergic pathways, we studied the natriuretic action and the suppressive effect of hANP on aldosterone secretion before and during treatment with haloperidol or pergolide in nude mice harbouring heterotransplanted human CONN's adenoma tissue. Nude mice with heterotransplanted tumour material without hormonal activity served as controls. The natriuretic efficacy of hANP remained unchanged by haloperidol or pergolide both in controls and in nude mice with heterotransplanted CONN's adenoma tissue. On the other hand, hANP had no effect upon the haloperidol-induced increase in aldosterone excretion in the control animals. Thus, preliminary evidence emerges that hANP has no effect on dopaminergic pathways and that the aldosterone inhibiting action of hANP is only of minor physiological significance.
D000236:Adenoma / Q000378:metabolism*; D000450:Aldosterone / Q000652:urine*; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009318:Natriuresis / Q000187:drug effects*; D009368:Neoplasm Transplantation; D010479:Pergolide / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000187:drug effects*
D011954:Receptors, Dopamine; D010479:Pergolide; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D006220:Haloperidol